ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2626

Identifying Homogeneous Endophenotypes in Childhood-Onset Systemic Lupus Erythematosus with Similarity Network Fusion

Nicholas C Chan1, Nicholas Gold2, Deborah Levy2, Andrea Knight3, Earl Silverman4, Daniela Dominguez5, Lawrence Ng2, Lauren Erdman2 and Linda Hiraki2, 1University of Toronto, Toronto, ON, Canada, 2The Hospital for Sick Children, Toronto, ON, Canada, 3Division of Rheumatology, The Hospital for Sick Children; Neurosciences and Mental Health, SickKids Research Institute; Department of Paediatrics, University of Toronto, Toronto, ON, Canada, 4Silverman, Toronto, ON, Canada, 5The Hospital for Sick Children, Toronto, Canada

Meeting: ACR Convergence 2024

Keywords: Pediatric rheumatology, Systemic lupus erythematosus (SLE)

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Monday, November 18, 2024

Title: Abstracts: Pediatric Rheumatology – Clinical II

Session Type: Abstract Session

Session Time: 3:00PM-4:30PM

Background/Purpose: Childhood-onset Systemic Lupus Erythematosus (cSLE) is a clinically heterogeneous autoimmune disease. We hypothesized that similarity network fusion (SNF) a data driven method would identify relatively clinically homogeneous subgroups of patients that may represent SLE endotypes with distinct genetics.

Methods: We included patients diagnosed with cSLE between January 1992-October 2023. All patients met 2019 ACR-EULAR classification criteria and were genotyped on an Illumina multiethnic array. Ungenotyped SNPs were imputed with TopMed as a referent. We extracted SLE manifestations, date of each manifestation onset and demographic characteristics from a dedicated Lupus database. Ancestry was genetically inferred using principal components and ADMIXTURE with 1000 Genomes as a referent. We used time to each SLE manifestation onset from SLE diagnosis to identify patient subgroups with SNF. We conducted Kaplan Meir analyses and ran Cox proportional-hazard models on the time from SLE diagnosis to onset of specific manifestations between SNF clusters. We tested cluster differences in demographic and manifestation prevalences using χ2 or Fisher’s exact test, and time to each SLE manifestation onset with log rank tests. We calculated additive, allelic weighted SLE non-HLA and HLA polygenic risk scores (PRS) using alleles from a transancestral GWAS of SLE. Models adjusted for sex and ancestry determined the relationship between PRS and cluster membership.

Results: Our cohort included 442 cSLE patients. 83% were female and the median age of SLE diagnosis was 13.6 years (Q1-Q3:12.0-15.8). Our cohort was primarily composed of patients of European (27%) and East Asian (26%) ancestry. SNF identified 2 clusters. The majority of patients in cluster 1 (n=203) were of European ancestry (42%) and cluster 2 (n=239) had a high prevalence of patients of East Asian (30%) and South Asian (22%) ancestry (P=3×10-9; Figure 1). Patients in cluster 2 had a higher prevalence, and earlier onset of class III/IV lupus nephritis, hypocomplementemia, fever, anti-dsDNA and anti-Smith antibodies compared to patients in cluster 1 (P< 1×10-7; Figure 2). The risk of developing 12 cSLE manifestations at any point in time was higher in patients in cluster 2 compared to cluster 1 (HR >1.4;P<4×10-3). SLE PRSs were not associated with cluster membership (Non-HLA SLE PRS: OR 0.9, 95% CI 0.8-1.2; P=0.5; HLA SLE PRS: OR 1.3, 95% CI 0.8-2.0;P=0.3).

Conclusion: In a large multiethnic cohort of cSLE patients, we used data-driven methods to identify two cSLE patient clusters. The cluster with more severe disease and earlier onset had a greater proportion East Asian and South Asian patients compared to the cluster with milder disease. Next steps include an HLA-wide analysis of cluster membership.

Supporting image 1

Figure 1. Ancestral Distribution Between Cluster 1 and 2, Represented Proportionally. Ancestry was genetically inferred using principal components with 1000 Genomes and the ADMIXTURE tool. Statistic preformed with a χ2 test, P<0.05.

Supporting image 2

Figure 2. Clinical and Laboratory SLE Manifestations With Different Prevalence Between SNF Clusters. “LN” stands for lupus nephritis and “Other Rashes” stands for maculopapular, discoid and cutaneous vasculitis rashes. Statistics performed with a Fisher’s Exact Test, Bonferroni corrected P<0.002.


Disclosures: N. Chan: None; N. Gold: None; D. Levy: AbbVie, 5, AstraZeneca, 5, Roche, 5, SOBI, 5; A. Knight: Pfizer, 6; E. Silverman: None; D. Dominguez: None; L. Ng: None; L. Erdman: None; L. Hiraki: Janssen, 2.

To cite this abstract in AMA style:

Chan N, Gold N, Levy D, Knight A, Silverman E, Dominguez D, Ng L, Erdman L, Hiraki L. Identifying Homogeneous Endophenotypes in Childhood-Onset Systemic Lupus Erythematosus with Similarity Network Fusion [abstract]. Arthritis Rheumatol. 2024; 76 (suppl 9). https://acrabstracts.org/abstract/identifying-homogeneous-endophenotypes-in-childhood-onset-systemic-lupus-erythematosus-with-similarity-network-fusion/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2024

ACR Meeting Abstracts - https://acrabstracts.org/abstract/identifying-homogeneous-endophenotypes-in-childhood-onset-systemic-lupus-erythematosus-with-similarity-network-fusion/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology